Q3 2018 EPS Estimates for Aclaris Therapeutics Inc (ACRS) Cut by Analyst

Aclaris Therapeutics Inc (NASDAQ:ACRS) – Analysts at William Blair reduced their Q3 2018 EPS estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday, October 16th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings of ($1.24) per share for the quarter, down from their previous forecast of ($1.14). William Blair also issued estimates for Aclaris Therapeutics’ Q4 2018 earnings at ($3.46) EPS, FY2018 earnings at ($6.71) EPS, FY2019 earnings at ($3.88) EPS and FY2020 earnings at ($2.50) EPS.

Several other equities analysts also recently commented on the company. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 17th. JMP Securities lowered their target price on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday. BidaskClub cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 31st. Finally, Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $41.60.

Aclaris Therapeutics stock opened at $12.50 on Thursday. Aclaris Therapeutics has a 12 month low of $11.00 and a 12 month high of $27.05. The company has a market capitalization of $377.04 million, a P/E ratio of -5.06 and a beta of 1.21.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The business had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million.

A number of hedge funds have recently modified their holdings of ACRS. FMR LLC increased its holdings in shares of Aclaris Therapeutics by 31.1% in the second quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock worth $67,015,000 after purchasing an additional 796,805 shares during the period. BlackRock Inc. increased its holdings in shares of Aclaris Therapeutics by 9.7% in the second quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock worth $46,163,000 after purchasing an additional 204,215 shares during the period. Rice Hall James & Associates LLC increased its holdings in shares of Aclaris Therapeutics by 88.5% in the second quarter. Rice Hall James & Associates LLC now owns 399,342 shares of the biotechnology company’s stock worth $7,975,000 after purchasing an additional 187,545 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Aclaris Therapeutics by 3,694.2% in the first quarter. JPMorgan Chase & Co. now owns 190,281 shares of the biotechnology company’s stock worth $3,333,000 after purchasing an additional 185,266 shares during the period. Finally, C WorldWide Group Holding A S increased its holdings in shares of Aclaris Therapeutics by 221.9% in the second quarter. C WorldWide Group Holding A S now owns 242,251 shares of the biotechnology company’s stock worth $4,838,000 after purchasing an additional 166,986 shares during the period. 99.75% of the stock is currently owned by institutional investors and hedge funds.

In other Aclaris Therapeutics news, Director Stephen A. Tullman bought 6,250 shares of the stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $15.97 per share, with a total value of $99,812.50. Following the acquisition, the director now directly owns 163,757 shares of the company’s stock, valued at approximately $2,615,199.29. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stephen A. Tullman bought 7,100 shares of the stock in a transaction on Thursday, October 4th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $99,400.00. Following the acquisition, the director now directly owns 177,457 shares in the company, valued at $2,484,398. The disclosure for this purchase can be found here. Insiders have acquired a total of 19,950 shares of company stock worth $298,213 in the last three months. Insiders own 17.00% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Featured Story: Why is insider trading harmful?

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply